Quality Assurance in Ovarian Cancer 2025

Quality Assurance in Ovarian Cancer 2025 - QS-OVAR 2025

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038147

Enrollment

1000

Registered

2025-10-14

Start date

2026-02-23

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C56

Interventions

Group 1: The subject of this voluntary quality assurance measure is the nationwide collection of data on of the surgical steps and systemic treatments used (chemotherapies and targeted therapies) in c

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Invasive epithelial ovarian cancer, fallopian tube, peritoneal cancer (including STIC lesions) or borderline tumours or rare ovarian malignancies including germ cell tumours and stromal cell tumours

Exclusion criteria

Exclusion criteria: Cancers of unknown primary Benign tumours of the ovary

Design outcomes

Primary

Measure	Time frame
Overall Survival	—

Secondary

Measure	Time frame
Success of Surgery Primary and Relapse chemotherapy as per the guidelines Relapse-free survival Survival following relapse Time from relapse to first and second subsequent treatments	—

Countries

Germany

Contacts

Public ContactPhilipp Harter

Kliniken Essen-Mitte Klinik für Gynäkologische Onkologie

office-wiesbaden@ago-ovar.de+49 201 174 – 34511

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026